Neurological complications after H1N1 influenza vaccination

Tin, Sim Sai; Wiwanitkit, Viroj

doi:10.1590/0004-282x20140150

Cited by 1 publication

(1 citation statement)

References 3 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, due to certain factors, including the immunological characteristics of the influenza vaccine itself, a small number of influenza vaccination subjects may develop diseases, including Guillain-Barré syndrome and narcolepsy, while obtaining immunoprotection. At present, to the best of our knowledge, the causes of these serious adverse reactions remain unclear (6,7).…”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibody against H1N1 influenza virus hemagglutinin cross reacts with hnRNPA1 and hnRNPA2/B1

Guo

Sun

Hao³

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

Following influenza A vaccination, certain individuals exhibit adverse reactions in the nervous system, which causes a problem with the safety of the influenza A vaccine. However, to the best of our knowledge, the underlying mechanism of this is unknown. The present study revealed that a monoclonal antibody (H1-84mAb) against the H1N1 influenza virus hemagglutinin (HA) protein cross-reacted with an antigen from brain tissue. Total brain tissue protein was immunoprecipitated with this cross-reactive antibody, and mass spectrometry revealed that the bound antigens were heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and hnRNPA2/B1. Subsequently, the two proteins were expressed in bacteria and it was demonstrated that H1-84mAb bound to hnRNPA1 and hnRNPA2/B1. These two proteins were expressed in three segments and the cross-reactivity of H1-84mAb with the glycine (Gly)-rich domains of hnRNPA1 (195aa-320aa) and hnRNPA2/B1 (202aa-349aa) was determined using ELISA blocking experiments. It was concluded that the Gly-rich domains of these two proteins are heterophilic antigens that cross-react with influenza virus HA. The association between the heterophilic antigen Gly-rich domains and the safety of influenza A vaccines remains to be investigated.

show abstract

Section: Introductionmentioning

confidence: 99%